Advisory Panel Vote Recommends FDA Approval of KETEK (telithromycin) Tablets for the Treatment of Respiratory Tract Infections
BRIDGEWATER, N.J. -- Aventis announces that the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend approval of KETEK (telithromycin) tablets (800 mg oral dose once daily) for the treatment of acute exacerbations of chronic bronchitis (once a day for five days), for the treatment of acute sinusitis (once a day for five days) and for the treatment of community-acquired pneumonia (once a day for seven to 10 days).
The Committee also voted by majority that the safety and efficacy data presented supported the use of KETEK for the treatment of penicillin- and macrolide-resistant strains of S. pneumoniae in community-acquired pneumonia and acute sinusitis.
The recommendations of the Advisory Committee are subject to discussion with the FDA to secure final labeling prior to the U.S. market introduction of KETEK.
"The positive recommendations and comments are a vote of confidence for KETEK and the company was commended for its commitment to bringing innovative drugs to patients and physicians. The Committee's decision was supported by the unprecedented body of global clinical trial and post- marketing data," said Frank Douglas, MD, executive vice president and chief scientific officer of Drug Innovation & Approval (DI&A) at Aventis. "We will continue to work with the FDA to bring this important new treatment to the healthcare community," he added.
KETEK is the first in a new class of antibiotics known as ketolides. KETEK was designed to deliver an optimal spectrum of activity, with a short treatment duration, specifically for upper and lower respiratory tract infections, including those caused by drug-resistant S. pneumoniae pathogens.
In clinical trials, the most commonly reported side effects (greater than or equal to 2 percent) were diarrhea, nausea and vomiting.
Safety and efficacy data evaluated by the Advisory Committee included Phase III studies involving 4,472 patients treated with KETEK, a controlled trial involving more than 24,000 patients in a "usual-care" setting, where approximately 12,000 were treated with KETEK (including patients at risk for complications), and post-marketing experience from more than 1.5 million exposures to KETEK in the EU and Latin America. KETEK was launched first in October 2001 in Germany and has been approved in all EU and major Latin American markets.
Source: Aventis
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
